Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MRTX1719 |
| Synonyms | |
| Therapy Description |
MRTX1719 inhibits the PRMT5-MTA complex, which potentially results in reduced tumor growth (PMID: 35041419). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MRTX1719 | MRTX-1719|MRTX 1719|BMS 986504|BMS986504|BMS-986504|BMS986504|Navlimetostat | PRMT5 Inhibitor 21 | MRTX1719 inhibits the PRMT5-MTA complex, which potentially results in reduced tumor growth (PMID: 35041419). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06672523 | Phase I | MRTX1719 | A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion | Recruiting | HUN | 0 |
| NCT05245500 | Phase I | MRTX1719 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Recruiting | USA | 0 |
| NCT07283705 | Phase II | MRTX1719 Gemcitabine + MRTX1719 + Nab-paclitaxel Fluorouracil + Irinotecan + MRTX1719 + Oxaliplatin | A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer | Not yet recruiting | USA | 0 |
| NCT06883747 | Phase I | MRTX1719 | Clinical Trial of BMS-986504 in Recurrent GBM Patients | Recruiting | USA | 0 |
| NCT06855771 | Phase II | MRTX1719 | A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion | Recruiting | USA | SWE | ROU | POL | ITA | GBR | FRA | ESP | DEU | AUS | 2 |